Document is current
Any future updates will be listed below
-
Authors
Moreno, Carol
Muñoz, Cecilia
Terol, María José
Hernández-Rivas, José-Ángel https://orcid.org/0000-0003-4550-757X
Villanueva, Miguel
-
Funding
Funding for this research was provided by:
Janssen-Cilag, S.A. (N/A)
- License Information
-
More Information
Article History
Received: 13 May 2021
Accepted: 24 September 2021
First Online: 15 October 2021
Declarations
:
: Not applicable
: Not applicable
: Carol Moreno is a consultant for Abbvie, Acerta, AstraZeneca, Janssen, Pharmacyclics and Sunesis; received speakers bureau fees from Abbvie and Janssen; and received grant/research support from Gilead, Janssen and Roche. Cecilia Muñoz is a consultant for Janssen. María José Terol is a consultant for Abbvie, Gilead, Janssen, Roche and Takeda; received grant/research support from Gilead and Janssen. José-Ángel Hernández-Rivas is a consultant for Abbvie, Amgen, AstraZeneca, Beigene, Celgene, Gilead, Janssen, Roche, Rovi and Takeda; received speakers bureau fees from Abbvie, Amgen, AstraZeneca, Celgene, Gilead, Janssen, Roche and Takeda; and received grant/research support from Celgene. Miguel Villanueva is an employee of Janssen-Cilag, S.A.
